NVO240705C80000
- 63.82
- 0.000.00%
Novo-Nordisk A/S Newsroom
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
Novo Nordisk Reprimanded in UK for Failure to Disclose Payments to Healthcare Sector
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.02% on an annualized basis producing an average annual return of 19.86%. Currently, Novo Nordisk has a market capitaliza
Novo Nordisk's Weight-Loss Drug Retains Safety Profile Despite Concerns -- Market Talk
1204 GMT - Novo Nordisk's semaglutide--the active ingredient in its blockbuster weight-loss and diabetes treatments--belongs to one of the most derisked therapeutic drug classes in history from a safe
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
Can it cause blindness? Research shows that the weight loss drug Ozempic is related to a rare blindness condition, and weight loss drug concept stocks have fallen.
Hidden risk of rare blindness.
A Harvard study shows a link between weight loss drug Ozempic and rare vision loss, causing a nearly 5% drop in novo-nordisk a/s stocks.
Some doctors have pointed out that there is currently no evidence to prove a direct causal relationship between drug use and eye complications, as some cases only appear after several months of medication.
US stocks closing | S&P, Nasdaq hit new highs again! Tesla rose nearly 35% in seven days, and Nvidia rose more than 4.5% overnight.
S&P has reached a new high for two consecutive days, NASDAQ has reached a new high for three consecutive days, and Dow's intraday decline has significantly narrowed. Google, Apple, Microsoft, Taiwan Semiconductor in the US stock market have all reached new highs. Tesla has risen by 35% in seven days, and the chip stock index has risen by nearly 2%.
Research warns of new risks with "miracle weight-loss drugs": there may be a correlation with a certain eye disease.
① The study came from the Massachusetts Eye and Ear Hospital in the US, a hospital that specializes in treating eye, ear, nose, throat, and head and neck diseases, and is also a teaching hospital affiliated to Harvard Medical School; ② The results showed that taking simeglutide prescriptions poses a potential risk of developing NAION, but further research is needed to assess the causal relationship.
Unusual Options Activity: AAL, RIVN and Others Attract Market Bets, AAL V/OI Ratio Reaches 170.7
EST Jul 3rd Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
Sector Update: Health Care Stocks Fall in Afternoon Trading
Health care stocks declined Wednesday afternoon with the NYSE Health Care Index shedding 1% and the Health Care Select Sector SPDR Fund (XLV) retreating 0.8%. The iShares Biotechnology ETF (IBB) fell
Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
A new observational study has identified a potential link between Novo Nordisk A/S's (NYSE:NVO) GLP-1 drugs, Ozempic and Wegovy (semaglutide), and a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss.
Top Midday Stories: Southwest Board Approves Shareholder Rights Plan; National Amusements Agrees to Preliminary Deal to Sell Paramount to Skydance; Ozempic, Wegovy Linked to Blinding Eye Condition, Study Says
The S&P 500 and the Nasdaq Composite were both up in late-morning trading Wednesday while the Dow Jones Industrial Average was down as investors prepare for another big jobs report Friday. In company
US stocks fluctuate | Shares related to weight loss drugs decline and Novo Nordisk (NVO.US) falls by more than 4%.
According to the Zhītōng Cáijīng APP, on Wednesday, stocks related to weight loss drugs fell. As of press time, Novo-Nordisk (NVO.US) fell more than 4%, Eli Lilly and Co (LLY.US) fell 1.6%, and Pfizer (PFE.US) fell 0.34%. Analysis by doctors at the Massachusetts Eye and Ear Hospital affiliated with Harvard University showed that Novo-Nordisk's popular weight loss drugs Ozempic and Wegovy appear to be associated with an increased risk of rare vision loss. Research on medical records shows that compared to those who use other weight loss drugs, those who use Novo-Nordisk's...
Novo Nordisk Shares See Further Drop; 'Study Links Ozempic To Higher Risk Of Eye Condition That Can Cause Vision Loss' - STAT News
A new observational study on Wednesday reported for the first time a potential link between Novo Nordisk's GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss.After hearing
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.6% to 1,436.74 on the S&P Europe Select ADR Index. From continental Europe, the
Ozempic, Wegovy Linked to Higher Risk of Blinding Eye Condition, Study Says
11:23 AM EDT, 07/03/2024 (MT Newswires) -- Ozempic, Wegovy Linked to Higher Risk of Blinding Eye Condition, Study Says Price: 138.67, Change: -4.31, Percent Change: -3.01
Express News | Novo Nordisk ADR fell 3.8% to the lowest since June 4th.
'Potential Link Between Ozempic, Wegovy And Serious Eye Condition Revealed In New Study' - New York Post
Researchers say they have uncovered a link between semaglutide — the active ingredient in Ozempic and Wegovy — and sudden vision loss.The risk of developing nonarteritic anterior ischemic optic neurop